No
Studies associated with:
| Division | Study Number | Title | Investigator(s) | Release Date |
|---|---|---|---|---|
| CTN | NIDA-CTN-0081 | Capturing Opioid Use Disorder Electronically & Patient Reported Outcomes (CODE-PRO) | Arjun Krishna Venkatesh, MD, MBA, MHS, Kathryn Hawk, M.D., M.H.S., Richard Andrew Taylor, MD, MHS | |
| CTN | NIDA-CTN-0079 | Emergency Department Connection to Care with Buprenorphine for Opioid Use Disorder (ED-CONNECT) | John Rotrosen, M.D., Kathryn Hawk, M.D., M.H.S., Ryan McCormack, M.D. | |
| CTN | NIDA-CTN-0064 | Assessing Long-term CTN-0049 Outcomes, HCV Prevalence and Progression along the HCV Care Continuum among HIV/HCV Co-infected Substance Users in the U.S. | Carlos del Rio, M.D., Carmen Masson, Ph.D., Daniel J. Feaster, Ph.D., David Perlman, M.D., Lisa Metsch, Ph.D. | |
| DTMC | NIDA-CSP-1033 | Phase 2, Multi-Center Trial of Lorcaserin in the Treatment of Cocaine Use Disorder | Shwe Gyaw, M.D. | |
| CTN | NIDA-CTN-0055 | Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study (CHOICES) | P. Todd Korthuis, MD | |
| CTN | NIDA-CTN-0051A2 | Treatment-as-Usual Opioid Use Outcomes Following Discharge from Detoxification and Short-Term Residential Programs Affiliated with NIDA CTN-0051 | John Rotrosen, M.D. | |
| CTN | NIDA-CTN-0067 | Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up | P. Todd Korthuis, MD | |
| CTN | NIDA-CTN-0075 | Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder | Li-Tzy Wu, Psy.D., Paolo Mannelli, MD | |
| DTMC | NIDA-CPU-0011 | Ph1 Marinol Interaction Study - Part 1 | Louis Cantilena, Jr., M.D, Ph.D. | |
| CTN | NIDA-CTN-0068 | Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder (ADAPT-2) | Madhukar H. Trivedi, M.D. | |
| CTN | NIDA-CTN-0054 | Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder (ADAPT) | Walter Ling, M.D. | |
| DTMC | NIDA-CPU-0010 | Assessment of Potential Interactions Between Intravenous Cocaine and Atomoxetine | Louis Cantilena, Jr., M.D, Ph.D. | |
| GRNT | NIDA-CENIC-P1S1 | Investigating the Impact of Nicotine Using Spectrum Cigarettes (P1S1) - Grant U54-DA031659 | Eric C. Donny, Ph.D. | |
| DTMC | NIDA-CTO-0011 | Double-Blind, Placebo-Controlled, Dose Response Trial Of Ondansetron For The Treatment Of Methamphetamine Dependence | Bankole Johnson, DSc., M.D., Ph.D. | |
| DTMC | NIDA-CTO-0012 | Phase 2, Double-Blind, Placebo-Controlled Trial Of Tiagabine For The Treatment Of Cocaine Dependence | Eugene Somoza, M.D. | |
| CTN | NIDA-CTN-0049 | Project HOPE - Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users | Lisa Metsch, Ph.D., Carlos del Rio, M.D. | |
| CTN | NIDA-CTN-0053 | Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment (ACCENT) | Kevin M. Gray, MD | |
| DTMC | NIDA-MDS-0002 | Assessment of Interactions Between Methamphetamine and Aripiprazole | Thomas F. Newton, M.D. | |
| DTMC | NIDA-CTO-0010 | Assessment of Potential Interactions Between Methamphetamine and Bupropion | Thomas F. Newton, M.D. | |
| DTMC | NIDA-CTO-0008 | Phase 2, Double-Blind Placebo-Controlled Trial Of Bupropion for the Treatment of Methamphetamine Dependence | Richard Rawson, Ph.D. | |
| DTMC | NIDA-CSP-1022 | Phase 2, Double-Blind, Placebo-Controlled Trial Of Selegiline Transdermal System (STS) As An Aid For Smoking Cessation | Elbert D. Glover, PhD, FASHA, FAAHB, FRIPH | |
| DTMC | NIDA-CSP-1021 | Double-Blind, Placebo-Controlled Multi-Center Trial Of Baclofen For The Treatment Of Cocaine Dependence | Liza Gorgon, M.A. | |
| DTMC | NIDA-CSP-1019 | Double-Blind, Placebo-Controlled Trial Of Selegiline Transdermal System For The Treatment Of Cocaine Dependence | Ahmed Elkashef, M.D., Paul J. Fudala, Ph.D. | |
| CTN | NIDA-CTN-0051 | Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment | John Rotrosen, M.D. | |
| DTMC | NIDA-MDS-0003 | Phase I, Double-Blind, Placebo-Controlled Assessment Of Potential Interactions Between Intravenous Cocaine And Ethanol And Oral Disulfiram | John D. Roache, Ph.D. | |
| DTMC | NIDA-CPU-0008 | Double-Blind, Placebo-Controlled Assessment of Interactions Between Intravenous Methamphetamine and Modafinil | Reese Jones, M.D. | |
| DTMC | NIDA-CTO-0007 | Phase 2, Double-Blind, Placebo-Controlled Trial Of Cabergoline For The Treatment Of Cocaine Dependence | Steven Shoptaw, Ph.D., Thomas F. Newton, M.D. | |
| DTMC | NIDA-CSP-1020 | A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal | Ann Montgomery, R.N. | |
| CTN | NIDA-CTN-0059 | The TAPS Tool: Screen and Brief Assessment Tool Validation Study | Robert P Schwartz, M.D., Li-Tzy Wu, Psy.D., Jennifer McNeely, M.D. | |
| CTN | NIDA-CTN-0056 | Testing and Linkage to HIV Care in China: A Cluster Randomized Trial | Zunyou Wu, MD, PhD | |
| DTMC | NIDA-CPU-0005 | Double-blind, placebo-controlled, safety and pharmacology study with 75 mg dosage of GBR 12909 in cocaine experienced African American Volunteers. | Louis Cantilena, Jr., M.D, Ph.D. | |
| DTMC | NIDA-CPU-0004 | Study of Interactions Between GBR 12909 and Cocaine | Kathryn Cunningham, Ph.D., John Grabowski, Ph.D. | |
| DTMC | NIDA-CPU-0006 | A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine | Reese Jones, M.D. | |
| DTMC | NIDA-CPU-0003 | Phase I, Double-Blind, Placebo-Controlled Dose Escalating Assessment of Potential Interactions Between Intravenous Cocaine and RPR 102681 | Louis Cantilena, Jr., M.D, Ph.D. | |
| DTMC | NIDA-CPU-0002 | Double-Blind, Placebo-Controlled, Dose Escalating, Safety and Pharmacology Study With Three Dosages of GBR 12909 in Cocaine Experienced Volunteers | Louis Cantilena, Jr., M.D, Ph.D. | |
| DTMC | NIDA-CTO-0006 | Cocaine-Metyrapone Interaction Study | Bonita Singal, M.D., T. John Winhusen, Ph.D. | |
| DTMC | NIDA-CTO-0005 | Double-Blind, Placebo-Controlled Trial Of Ondansetron For The Treatment Of Cocaine Dependence | John D. Roache, Ph.D. | |
| DTMC | NIDA-CTO-0004 | Assessment Of Potential Interactions Between Intravenous Methamphetamine And Oral Selegiline | Thomas F. Newton, M.D. | |
| DTMC | NIDA-CTO-0003 | Assessment Of Potential Interactions Between Intravenous Cocaine And Tolcapone | Thomas F. Newton, M.D. | |
| DTMC | NIDA-CTO-0002 | Safety Evaluation Of Cocaine Treatment Medication, Modafinil: Interactions With Intravenous Cocaine | Robert J. Malcolm, M.D., C. Lindsay DeVane, Pharm.D. | |
| CTN | NIDA-CTN-0017 | HIV and HCV Risk Reduction Interventions in Drug Detoxification and Treatment Settings | Robert Booth, Ph.D. | |
| CTN | NIDA-CTN-0047 | Screening, Motivational Assessment, Referral, and Treatment in Emergency Departments (SMART-ED) | Michael P. Bogenschutz, M.D., Dennis Donovan, Ph.D. | |
| CTN | NIDA-CTN-0018 | Reducing HIV/STD Risk Behaviors: A Research Study for Men in Drug Abuse Treatment | Donald A. Calsyn, Ph.D. | |
| DTMC | NIDA-MDS-0007 | Phase 2, Double-Blind, Placebo-Controlled Trial Of Bupropion For Methamphetamine Dependence | Ann Anderson, M.D. | |
| DTMC | NIDA-MDS-0004 | Phase 2, Double-Blind, Placebo-Controlled Trial Of Modafinil For The Treatment Of Cocaine Dependence | Domenic Ciraulo, M.D. | |
| DTMC | NIDA-CTO-0001 | Phase 2, Double-Blind, Placebo-Controlled Trial Of Reserpine For The Treatment Of Cocaine Dependence | Eugene Somoza, M.D. | |
| CTN | NIDA-CTN-0052 | A Randomized Controlled Evaluation of Buspirone for Relapse-Prevention in Adults with Cocaine Dependence (BRAC) | T. John Winhusen, Ph.D. | |
| CTN | NIDA-CTN-0048 | Cocaine Use Reduction with Buprenorphine (CURB) | Walter Ling, M.D. | |
| CTN | NIDA-CTN-0046 | Smoking-Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking-Cessation and Stimulant Treatment on Stimulant-Dependence Outcomes | T. John Winhusen, Ph.D., Eugene Somoza, M.D. | |
| CTN | NIDA-CTN-0044 | Web-delivery of Evidence-Based, Psychosocial Treatment for Substance Use Disorders | Edward V. Nunes, M.D. | |
| CTN | NIDA-CTN-0037 | Stimulant Reduction Intervention using Dosed Exercise (STRIDE) | Madhukar H. Trivedi, M.D. | |
| CTN | NIDA-CTN-AWARE | Project Aware: HIV Rapid Testing & Counseling in STD Clinics in the U.S. – an Adaptation of CTN-0032 | Lisa Metsch, Ph.D., Grant Colfax, M.D. | |
| CTN | NIDA-CTN-0032 | HIV Rapid Testing and Counseling in Drug Abuse Treatment Programs in the U.S. | Lisa Metsch, Ph.D. | |
| CTN | NIDA-CTN-0031A | An Evaluation of Neurocognitive Function, Oxidative Damage, and Their Association With Treatment Outcomes in Methamphetamine and Cocaine Abusers | T. John Winhusen, Ph.D., Eugene Somoza, M.D. | |
| CTN | NIDA-CTN-0031 | Stimulant Abuser Groups to Engage in 12-Step (STAGE-12): Evaluation of a Combined Individual-Group Intervention to Reduce Stimulant and Other Drug Use by Increasing 12-Step Involvement | Dennis Donovan, Ph.D., Dennis Daley, Ph.D. | |
| CTN | NIDA-CTN-0030A3 | Long-Term Follow-Up to CTN-0030 (A Two-Phase Randomized Controlled Clinical Trial of Buprenorphine/Naloxone Treatment Plus Individual Drug Counseling for Opioid Analgesic Dependence) | Roger Weiss, M.D., Jennifer Sharpe Potter, Ph.D. | |
| CTN | NIDA-CTN-0030 | A Two-Phase Randomized Controlled Clinical Trial of Buprenorphine/Naloxone Treatment Plus Individual Drug Counseling for Opioid Analgesic Dependence | Walter Ling, M.D., Roger Weiss, M.D. | |
| CTN | NIDA-CTN-0029 | A Pilot Study of Osmotic-Release Methylphenidate in Initiating and Maintaining Abstinence in Smokers with ADHD | T. John Winhusen, Ph.D., Eugene Somoza, M.D. | |
| CTN | NIDA-CTN-0028 | Osmotic-Release Methylphenidate (OROS-MPH) for ADHD in Adolescents with Substance Use Disorders | Paula Riggs, M.D. | |
| CTN | NIDA-CTN-0027 | Starting Treatment with Agonist Replacement Therapies (START) | Walter Ling, M.D. | |
| CTN | NIDA-CTN-0021 | Motivational Enhancement Treatment to Improve Treatment Engagement and Outcome for Spanish-Speaking Individuals Seeking Treatment for Substance Abuse | Kathleen Carroll, Ph.D., José Szapocznik, Ph.D. | |
| CTN | NIDA-CTN-0020 | Job Seekers Training for Patients with Drug Dependence | Dace Svikis, Ph.D. | |
| CTN | NIDA-CTN-0019 | Reducing HIV/STD Risk Behaviors: A Research Study for Women in Drug Abuse Treatment | Susan Tross, Ph.D. | |
| CTN | NIDA-CTN-0016 | Patient Feedback: A Performance Improvement Study in Outpatient Addiction Treatment | Robert Forman, Ph.D. | |
| CTN | NIDA-CTN-0015 | Women's Treatment for Trauma and Substance Use Disorders | Denise Hien, Ph.D. | |
| CTN | NIDA-CTN-0014 | Brief Strategic Family Therapy (BSFT) For Adolescent Drug Abusers | José Szapocznik, Ph.D. | |
| CTN | NIDA-CTN-0013 | Motivational Enhancement Therapy (MET) to Improve Treatment Utilization and Outcome in Pregnant Substance Users | T. John Winhusen, Ph.D. | |
| CTN | NIDA-CTN-0012 | Characteristics of Screening, Evaluation, and Treatment of HIV/AIDS, Hepatitis C Viral Infections, and Sexually Transmitted Infections in Substance Abuse Treatment Programs | Lawrence Brown, Jr., M.D., M.P.H. | |
| CTN | NIDA-CTN-0011 | A Feasibility Study of a Telephone Enhancement Procedure (TELE) to Improve Participation in Continuing Care Activities | Robert L. Hubbard, Ph.D., M.B.A. | |
| CTN | NIDA-CTN-0010 | Buprenorphine/Naloxone-Facilitated Rehabilitation for Opioid Dependent Adolescents/Young Adults | George Woody, M.D. | |
| CTN | NIDA-CTN-0009 | Smoking Cessation Treatment with Transdermal Nicotine Replacement Therapy in Substance Abuse Rehabilitation Programs | Malcolm Reid, Ph.D. | |
| CTN | NIDA-CTN-0008 | Assessment of the National Drug Abuse Clinical Trials Network: A Baseline for Investigating Diffusion of Innovation | Dennis McCarty, Ph.D. | |
| CTN | NIDA-CTN-0007 | Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone Clinics | Maxine Stitzer, Ph.D. | |
| CTN | NIDA-CTN-0006 | Motivational Incentives for Enhanced Drug Abuse Recovery: Drug Free Clinics | Maxine Stitzer, Ph.D. | |
| CTN | NIDA-CTN-0005 | MI (Motivational Interviewing) to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse | Kathleen Carroll, Ph.D. | |
| CTN | NIDA-CTN-0004 | MET to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse | Kathleen Carroll, Ph.D. | |
| CTN | NIDA-CTN-0003 | Suboxone (Buprenorphine/Naloxone) Taper: A Comparison of Two Schedules | Walter Ling, M.D. | |
| CTN | NIDA-CTN-0002 | Buprenorphine/Naloxone versus Clonidine for Outpatient Opiate Detoxification | Walter Ling, M.D. | |
| CTN | NIDA-CTN-0001 | Buprenorphine/Naloxone versus Clonidine for Inpatient Opiate Detoxification | Walter Ling, M.D. | |
| DTMC | NIDA-CSP-1026 | Phase 2, Double-Blind, Placebo-Controlled Trial Of Modafinil For Methamphetamine Dependence | Ahmed Elkashef, M.D. | |
| DTMC | NIDA-CSP-1025 | Phase 2, Double-Blind, Placebo-Controlled Trial Of Topiramate For The Treatment Of Methamphetamine Dependence | Bankole Johnson, DSc., M.D., Ph.D. | |
| DTMC | NIDA-CSP-1018 | A Multicenter Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence | Walter Ling, M.D., Paul J. Fudala, Ph.D., Paul Casadonte, M.D. | |
| DTMC | NIDA-CSP-1008B | A Multicenter Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence | Peter Bridge, M.D. | |
| DTMC | NIDA-CSP-1008A | A Multicenter Efficacy/Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence | Peter Bridge, M.D., Paul J. Fudala, Ph.D. | |
| DTMC | NIDA-CSP-999 | A Multicenter Clinical Trial of Buprenorphine in Treatment of Opiate Dependence | Walter Ling, M.D., Donald R. Wesson, M.D., C. James Klett, Ph.D. | |
| DTMC | NIDA-CPU-0016 | Double-Blind, Placebo-Controlled Assessment Of Potential Interactions Between Intravenous Methamphetamine And Osmotic-Release Methylphenidate (Oros-Mph) | Eugene Somoza, M.D. |